非达霉素
Tier C — Watch / tradeFidaxomicin · all drugs expiring in 2028 →
Targets：RNAP
Brand：Dafclir、Dificid、Dificlir
Indications (approved)：艰难梭菌感染、肠炎、腹泻
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| FIDA-001 | - | - |
Frequently asked questions
What are the approved indications of Fidaxomicin?
Approved indications include: 艰难梭菌感染, 肠炎, 腹泻.
When does the Fidaxomicin patent expire?
Based on public sources, the Fidaxomicin patent expires in 2028.
How many synthesis routes are recorded for Fidaxomicin?
1 synthesis routes are recorded; the shortest is 1 steps with 4.24 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Fidaxomicin intermediates?
All intermediates in Fidaxomicin routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Fidaxomicin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24